Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07890311) titled 'Single-arm, Multicenter, Open-label Phase II Study of Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract Cancer' on Oct. 16.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Jiangmen Central Hospital

Condition: Biliary Tract Neoplasms

Intervention: Biological: MRG003 (Becotatug Vedotin)

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: September 22, 2026

Target Sample Size: 30

Countries of Recruitment: China

To know more, vis...